PowerPoint-Präsentation - Sartorius · Agenda 01 Sartorius in Brief 03 Lab Products & Services 02...
Transcript of PowerPoint-Präsentation - Sartorius · Agenda 01 Sartorius in Brief 03 Lab Products & Services 02...
1
Company PresentationApril 2017
Agenda
Sartorius in Brief01
03 Lab Products & Services
Bioprocess Solutions02
04 Sartorius 2020
05 Appendix
Sartorius in 2016
Figures as of Dec. 31, 2016; 1 Underlying EBITDA (excluding extraordinary items)
~€325 mnEarnings1
~€1.3 bnSales revenue
Bioprocess and Laboratory Technologies Provider
Internationally leading
EBITDA1 margin
Sales revenue by region
~€152 mnInvestments
~34%Americas
~44%EMEA
~22%Asia | Pacific
25.0 %
Listed since 1990; Part of German TecDax
3
Global Player with around 50 Sales and Production Sites
AmericasCanada | USA: Mas-sachusetts | Michigan | New York, New Mexico, North Carolina, Pennsyl-vania, Colorado | Puerto Rico | Mexico | Peru | Brazil | Argentina
Production and Production/Sales
India | Thailand | Singapore | Vietnam | China | Malaysia | South Korea | Japan | Australia
Netherlands | Belgium | Ireland | UK | France | Spain | Sweden | Finland | Denmark | Germany | Poland | Austria | Hungary | Switzerland | Italy | Russia | Tunisia
EMEA
Asia|Pacific
Sales 4
More than 6,900 Employees Worldwide
Figures as of Dec. 31, 2016 5
~1,000Americas
~4,850EMEA
~1,050Asia|Pacific
Discover Sartorius1995
1996
~7,0003,000 4,000 5,0002,000
1997 1998 1999 2001 20062002 2003 2004 2005 2008 20132009 2010 2011 2014
2000 2007 2012 20152016
2017
Our Corporate Values
6
Roots of Both Divisions Reach Far Back
Weighing TechnologyCore of Lab Division
Filtration Mainstay of Bioprocess Division
University mechanician | Company founder Florenz Sartorius invents short-beam analytical balance
Wilhelm Sartorius founds joint venture with Nobel laureate and creator of membrane filtrationRichard Zsigmondy
1870 1927
7
8
1870 Florenz Sartorius foundsprecision machine workshop
2007 Biotechnology Division merges withStedim to Sartorius Stedim Biotech1927 Membrane filter
company is founded2011 New Division Lab Products & Services; Acquisition Biohit LH
since 2012 Six Acquisitionsin Bioprocess Solutions1990 Initial public
offering
Rebuilding after Second World War
Mid-90s Positioning asbiopharma supplier
2000 Acquisitionof B. Braun‘s fer-mentation business
Core companyin Goettingen
Expansion into Asia Around 50 sitesworldwide
Internationaldistribution
Subsidiaries in Europe | North America
1870 199519801930 Today
Business Development Spanning More Than 140 Years
2016 Acquisitions ofIntelliCyt and ViroCyt
2017 Acquisitions ofEssen BioScience andUmetrics
Two Divisions
Share of Group sales based on figures as of Dec. 31, 2016 9
Premium lab instruments, consumables and services for R&D, QA and QC
Lab Products & ServicesBioprocess Solutions
~75%of sales
~25%of sales
Innovative single-use prodcts andequipment for the manufacture of biologics
Agenda
Sartorius in Brief01
03 Lab Products & Services
Bioprocess Solutions02
04 Sartorius 2020
05 Appendix
What Are Biopharmaceuticals?
11
First-time or improved treatment of serious illnesses, such as cancer, multiple sclerosis, rheumatism Targets only diseased cells; fewer side effects New vaccines
~20.000 Atoms
R&D and production labor-intensive
High therapy costs: biologics ~ $50 vs. chemical medications ~ $2 per day
Living, geneticallymodified cells Production Injection | Infusion
Advantages Challenges
High initial cost
Considerable cleaning effort
Risk of cross-contamination
12
Trend towards Manufacturing Single-use Technologies
PresentPast
+ CAPEX reduction over entire lifecycle
+ Lower water and energy consumption
+ Higher flexibility
BPS Generates Around 75% of its Business with Single-use Products
~ €975mn.Single-use~ 75 %
Equipment~25 %
13Figures as of Dec. 31, 2016
Total Solution Provider across the Biopharma Process Chain
14
Services
Process Development Production
Fermentation PurificationCell Harvesting Buffer | PreparationCell Culture Media
Leading Market Positions Worldwide
>85 % of sales revenue generated from TOP 1-3 positions
Filtration TOP 3 Fluid Management #1 Fermentation #1
15
Agenda
Sartorius in Brief01
03 Lab Products & Services
Bioprocess Solutions02
04 Sartorius 2020
05 Appendix
Research Labs Need Intelligent Lab Instruments
17
Assistance systems reduce user errors
Laboratory data are processedautomatically
Ergonomic design minimizes physicalstrain
Quality Assurance Labs Accompany every Step of Food andPharma Production
18
Sample collection
Quality assurance
Clearance
Documentation
These Products and Services are Must-Haves in Any Laboratory
19
Balances Pipettes Lab Water Systems Moisture Analyzers
Lab Instruments Consumables Services Syringe Filters Microbiological
Test Kits Pipette Tips
Installation Servicing | Repair Qualification (IQ/OQ) Calibration Training
Lab Portfolio Recently Expanded into Bioanalytics
20
Innovative and unique bioanalytical platforms, combined from instruments, reagents and software
Focus on customers from pharma/biotech and academia
Excellent fit between the two acquired companies and with existing LPS portfolio
Award-winning technology for cell screening
Unique system for real-timelive-cell imaging and analysis
Acquisition in June 2016
Acquisition in July 2016
Acquisition in April 2017
Innovative platform for rapid virus quantification
Expansion of Direct Sales including eBusiness
Distributors
optimize
Direct salesexpand
eBusinessbuild upSa
les
Chan
nels
Pharma | Biotech
Academia
Cl. Diagnostics | Chemicals
Food & Beverage
Leading Market Positions Worldwide
Average global market share >10%
Significant growth potential, especially in USA and Asia
Lab Balances #2 Pipettes #4 Lab Filtration #3 Microb. Analysis #2(membrane based)
22
Agenda
Sartorius in Brief01
03 Lab Products & Services
Bioprocess Solutions02
04 Sartorius 2020
05 Appendix
Profitable Growth in Past 10 Years
1Underlying EBITDA (adjusted for extraordinary items); 2 Including Intec (Intec sales revenue = shaded area) 24
521.1
622.7 611.6 602.1659.3
733.1
845.7887.3 891.2
13.715.3
13.114.1
16.718.6 19.0 19.5
21.0
23.625.0
0
5
10
15
20
25
30
35
40
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 20162
Sales revenue € in mn Underlying EBITDA1 margin in %
1,300.3
1,114.8
Ambitious Growth Targets Up to 2020
1 Based on 2015 exchange rates; 2 Excluding extraordinary items 25
Regional North America: Gain market share Asia | esp. China: Leverage strong market growth
Strategic Initiatives 2020 Targets
Portfolio Expansion through alliances and acquisitions Own product development
Infrastructure Expansion of production capacity New global ERP system
~€2bn.Sales Revenue
~26 - 27% EBITDA2 margin
~3/4Organic
~1/4 Acquisitions
1
1
Gain Market Share in North America; Leverage Strong Market Growth in Asia
1 2011-2016, in constant currencies 2 Figures as of Dec. 31, 2016 26
Sales share2
Americas
Asia | Pacific
~€1.3 bn.
34%
22%
Regional
~+18%CAGR1 Americas
~+14%CAGR1 Asia | Pacific
North America: largest market for biopharma and lab products
Asia: strongest-growing pharma and lab market
Mississauga
Mexico CityYauco
Bohemia
Albuquerque
Production | Sales Sales
SingaporeKuala Lumpur
Bangalore
Hanoi
TokyoBeijing Seoul
Hong KongBangkok
ShanghaiSuzhou
Production | Sales Sales
New OxfordAnn Arbor
Complementary Alliances & Acquisitions Add to Growth
27
Acquisitions | Alliances
27
Portfolio
20172000
Aseptic Technologies
Metroglas
LevTech
SAFC Biosciences
Raumedic
Südpack Medica
B. Braun Biotech International
OmnimarkCorning
c-LEcta
Umetrics
ABER
ProMetic
BlueSens
TC Tech
Biohit Liquid Handling
Lonza Cell Culture Media
TAP Biosystems
BD
AllPure
em-tec
BioOutsource
Cellca
kSep
ViroCyt
IntelliCyt
Essen BioScience
Toha Plast
Stedim Biosystems
Wave Biotech
Bayer Technology Services
NIR Online
Bosch Packaging
Trace Analytics
The Widest Product Portfolio Across the Biopharma Process Chain
Cell culture media Cell
Media Preparation
Seed Fermentation
ProductionFermentation
Cell Removal | Clarification
ViralClearance
y y
y yy
y
y
yy
yy
y
y y
y
yy
y
y
Antibodies Contaminents such as viruses
Simplified diagram
y y
yy
Media Preparation
Seed Fermentation
ProductionFermentation
Cell Removal Clarification
Capture Polishing VirusClearance
Downstream Processing Upstream Processing
Vaccines, monoclonalantibodies, ...
Process development
Portfolio
28
Support of processdevelopment Q3 2015
Testing in biosafety andbioanalytics Q2 2015
Small-scale single-use bioreactors Q4 2013
Cell culture mediaQ1 2013
Single-use technologyfor samplingQ2 2014
Bioprocess Portfolio Continuously Enhanced
Process Development Production
Software for bioprocessdata analysisQ2 2017
Single-usecentrifugesQ3 2016
29
Alliances Speed up Innovation
30
Portfolio
Development and supply partnership for novel polymer plastic films
Ready-to-use, prefilled media products formicrobiological applications
Single-use sensors for biomass measurement
New Products
31
Single-use Clarification SystemHigh flow rates, flexible scalability
Portfolio
Innovative Operating ConceptsFast and reliable results
Syringeless One-step FiltersSimple, multiplexing sample preparation
Modular Fermentation System Parallel use of up to eight su bioreactors
Strong R&D in Core Technologies
3232
Portfolio
Membranes, non-wovens Plastics processing: Injection
molding, extrusion, welding|gluing Sensors, automation & control Bioanalytics & cell biology Process analytics Mechatronics
Technologies
Biotechnology and biopharma Quality assurance and research
laboratories Technology integrationAlliances
Applications
1 2 Based on FY 2017 guidanceIncl. discontinued operation; 3333
Infrastructure
Investments into Infrastructure Foster Profitable Growth
Significant expansion of production capacities initiated in 2016; earlier and to a greater extent than initially planned due to continuing strong organic growth
Capacities at Yauco plant for single-use bags and filters will be more than doubled Expansion of operations at headquarters in Goettingen, e.g. additional membrane
capacities Further investments into digitalization (ERP, CRM, etc)
Capex ratio in %
8.8
201620142013120121
7.7
2015
~ 12-15
2017e2
11.79.1
10.1Expansion
Production facility in Yauco | Puerto Rico
New Sartorius Campus to Further Boost Innovative Strength and Efficiency
34
Consolidation of the two major Goettingen sites into one site
New lab instruments building in operation
Further expansion of filter and membrane production capacity
Building to foster an advanced and open work environment and to provide more space
Infrastructure
Agenda
35
Sartorius in Brief01
03 Lab Products & Services
Bioprocess Solutions02
04 Sartorius 2020
05 Appendix
Expansion in Stages of Sartorius Campus
36
Lab Instruments Manufacturing
Parking Lot
R&D Membrane production
CollegeFacility
Management
Main Entrance | Administration- under constr. -
Receiving area
Membranecasting machine
Bioprocess Solutions Manufacturing
Marketing | Cafeteria
- under constr. -
Infrastructure
Existing buildingsNew Buildings
Next Steps
37
Main Entrance | Administration
Marketing | Cafeteria
Under Construction
New main entrance and administration buildings:completion and relocation in Q3 2017
Forum with application labs, offices, cafeteria; expected to be operational by end of 2018
Infrastructure
38
Portfolio Bioprocess Solutions
Filtration Purification
39
Fluid Management Fermentation & Cell Culture Media
Portfolio Bioprocess Solutions
40
Portfolio Lab Products & Services
Lab Balances Pipettes
41
Lab Water Systems Further Lab Instruments
Portfolio Lab Products & Services
Bioanalytical Technologies
42
Lab Filtration Microbiological Quality Control
Portfolio Lab Products & Services
Questions & Answers
43
Disclaimer
This presentation contains statements concerning Sartorius Groups’ future performance. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is because our assumptions harbor risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements.
Throughout this presentation, differences may be apparent as a result of rounding during addition.
44